Vaccines,
Journal Year:
2022,
Volume and Issue:
10(12), P. 2138 - 2138
Published: Dec. 13, 2022
Early
and
effective
diagnosis
of
cancer
is
decisive
for
its
proper
management.
In
this
context
biomarker-based
budding
as
one
the
promising
ways
early
detection,
disease
progression
monitoring,
therapy.
Integration
Biosensing
devices
with
different
metallic/nonmetallic
nanoparticles
offers
amplification
multiplexing
capabilities
simultaneous
detection
biomarkers
(CB’s).
This
study
provides
a
comprehensive
analysis
most
recent
designs
fabrication
methodologies
designed
developing
electrochemical
biosensors
(EB)
cancers.
The
role
in
therapeutics
also
discussed.
Journal of Controlled Release,
Journal Year:
2024,
Volume and Issue:
378, P. 438 - 459
Published: Dec. 21, 2024
Cancer
vaccines
are
promising
therapeutic
approaches
to
enhance
specific
T-cell
immunity
against
most
solid
tumors.
By
stimulating
anti-tumor
immunity,
clearing
minimal
residual
disease,
and
minimizing
adverse
effects,
these
target
tumor
cells
effective
when
combined
with
immune
checkpoint
blockade
or
other
immunotherapies.
However,
the
development
of
cell-based
faces
quality
issues
due
poor
immunogenicity,
heterogeneity,
a
suppressive
microenvironment,
ineffective
delivery
methods.
In
contrast,
extracellular
vesicles
(EVs),
naturally
released
by
cells,
considered
ideal
drug
carriers
vaccine
platforms.
EVs
offer
highly
organ-specific
targeting,
induce
broader
more
responses,
demonstrate
superior
tissue
ability.
The
EV
is
crucial
for
advancing
cancer
immunotherapy.
Compared
vaccines,
produced
under
Good
Manufacturing
Practices
(GMP)
advantages
such
as
high
safety,
ease
preservation
transport,
wide
range
sources.
This
review
summarizes
latest
research
findings
on
potential
applications
in
this
field.
It
also
highlights
novel
neoantigens
cancer.
Vaccines,
Journal Year:
2022,
Volume and Issue:
10(10), P. 1691 - 1691
Published: Oct. 10, 2022
Extracellular
vesicles
(EVs)
produced
by
various
immune
cells,
including
B
and
T
macrophages,
dendritic
cells
(DCs),
natural
killer
(NK)
mast
mediate
intercellular
communication
have
attracted
much
attention
owing
to
the
novel
delivery
system
of
molecules
in
vivo.
DCs
are
among
most
active
exosome-secreting
system.
EVs
cancer
contain
antigens;
therefore,
development
vaccine
therapy
that
does
not
require
identification
antigens
using
cancer-cell-derived
may
significant
clinical
implications.
In
this
review,
we
summarise
molecular
mechanisms
underlying
EV-based
responses
their
therapeutic
effects
on
tumour
vaccination.
Cancers,
Journal Year:
2022,
Volume and Issue:
14(20), P. 5098 - 5098
Published: Oct. 18, 2022
Cutaneous
squamous
cell
carcinoma
(cSCC)
as
one
of
the
most
prevalent
cancers
worldwide
is
associated
with
significant
morbidity
and
mortality.
Full-body
skin
exam
biopsy
gold
standard
for
cSCC
diagnosis,
but
it
not
always
feasible
given
constraints
on
time
costs.
Furthermore,
fails
to
reflect
dynamic
changes
in
tumor
genomes,
which
challenges
long-term
medical
treatment
patients
advanced
diseases.
Extracellular
vesicle
(EV)
an
emerging
biological
entity
oncology
versatile
clinical
applications
from
screening
treatment.
In
this
systematic
review,
pre-clinical
studies
cSCC-derived
EVs
were
summarized.
Seven
genomics,
transcriptomics,
proteomics
identified.
The
contents
may
mutational
landscape
original
cancer
cells
or
be
selectively
enriched
EVs.
Desmoglein
2
protein
(Dsg2)
important
molecule
biogenesis
Ct-SLCO1B3
mRNA,
CYP24A1
circular
RNA
(circRNA)
are
EVs,
suggesting
potentials
diagnosis.
p38
inhibited
cSCC-associated
long
intergenic
non-coding
(linc-PICSAR)
Dsg2
involved
EV-mediated
invasion
drug
resistance
served
prognostic
therapeutic
predictors.
We
also
proposed
future
directions
devise
EV-based
based
these
molecules
preliminary
other
cancers.
Vaccines,
Journal Year:
2022,
Volume and Issue:
10(12), P. 2138 - 2138
Published: Dec. 13, 2022
Early
and
effective
diagnosis
of
cancer
is
decisive
for
its
proper
management.
In
this
context
biomarker-based
budding
as
one
the
promising
ways
early
detection,
disease
progression
monitoring,
therapy.
Integration
Biosensing
devices
with
different
metallic/nonmetallic
nanoparticles
offers
amplification
multiplexing
capabilities
simultaneous
detection
biomarkers
(CB’s).
This
study
provides
a
comprehensive
analysis
most
recent
designs
fabrication
methodologies
designed
developing
electrochemical
biosensors
(EB)
cancers.
The
role
in
therapeutics
also
discussed.
